Plain-English translation of NCT03872401 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a medication designed to lower cholesterol levels in the blood, to see if it could reduce the risk of major heart problems in people at high risk but who had not yet experienced a heart attack or stroke. About 12,000 adults participated in this study. Participants received either the medication or a placebo (a dummy injection) every two weeks to see if lowering cholesterol could prevent future heart events.
Many people at high risk for heart disease still experience heart attacks or strokes even when taking standard cholesterol medications. This trial was designed to find out whether this medication could provide additional protection by lowering cholesterol even further and preventing dangerous cardiovascular events.
Participants in this trial received an injection under the skin every two weeks for the duration of the study. Half of the participants received the active medication (), and half received a placebo, with neither they nor the researchers knowing which group they were in. The trial followed participants over time to track whether they experienced any major heart events, such as heart attacks or strokes, and measured their cholesterol levels throughout the study.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States